Spencer Z. Rosero
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Spencer Z. Rosero has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Mehmet Kemal Aktas
University of Rochester Medical Center
3 shared publications - Valentina Kutyifa
Department of Medicine, Cardiology Division, University of Rochester Medical Center , Rochester, NY
3 shared publications - Arwa Younis
Cleveland Clinic
2 shared publications - Bronislava Polonsky
University of Rochester Medical Center
2 shared publications - David T. Huang
University of Rochester Medical Center
2 shared publications - Ido Goldenberg
Clinical Cardiovascular Research Center University of Rochester, Rochester New York USA
2 shared publications
Latest Publications
- Open Access
- 1 October 2025
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 11 (5) , e200292
Study of Testosterone and Recombinant Human Growth Hormone in Facioscapulohumeral Muscular Dystrophy
Effective therapies for facioscapulohumeral muscular dystrophy (FSHD) are currently limited. Recombinant human growth hormone (rHGH) combined with testosterone (combination therapy) may have meaningful clinical effects on ambulation, strength, muscle mass, and disease burden. As such, combination therapy has the potential to limit disease progression and functional decline in individuals with muscular dystrophy. The objective of this study was to evaluate the safety, tolerability, and potential efficacy of combination therapy in adult men with FSHD. This investigator-initiated, single-center (University of Rochester), single-arm, proof-of-concept study evaluated the safety and tolerability of combination therapy in ambulatory adult men with FSHD. Participants received daily rHGH combined with testosterone enanthate injections every 2 weeks for 24 weeks, followed by a 12-week washout period. Participants underwent serial safety and laboratory assessments to monitor safety and tolerability during the study. Participants were also evaluated for changes from baseline in lean body mass (LBM) and fat mass, measured by dual-energy X-ray absorptiometry; ambulation, measured by 6-minute walk distance; strength; clinical function, measured using the FSHD-Composite Outcome Measure (FSHD-COM); and patient-reported disease burden, measured by the FSHD Health Index (FSHD-HI). Nineteen of 20 participants completed the study, with no participants experiencing a serious adverse event. The most common adverse event was mild injection site reaction at the rHGH and/or testosterone injection site. After 24 weeks, LBM improved by 2.21 kilograms (95% CI 1.35-3.07; p < 0.0001), fat mass decreased by 1.30 kilograms (95% CI -2.56 to -0.04; p = 0.04), 6-minute walk distance increased by 37.3 m (95% CI 18.3-56.9; p = 0.001), overall strength (average % of predicted normal) increased by 3% (95% CI 0.3-5.6; p = 0.03), clinical function (FSHD-COM) improved by 2.4 points (95% CI 4.0-0.8; p = 0.006), and total disease burden (FSHD-HI) decreased by 6.1 points (95% CI -12.0 to -0.2; p = 0.04). Combination therapy was safe and well tolerated in men with FSHD. Participants experienced improvements in ambulation, strength, muscle mass, and disease burden after receiving this study intervention. Larger randomized, double-blind, placebo-controlled trials are needed to further investigate this promising therapeutic approach. Registered on ClinicalTrials.gov: NCT03123913.
- 1 October 2025
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 11 (5) , e200292
Open AccessStudy of Testosterone and Recombinant Human Growth Hormone in Facioscapulohumeral Muscular Dystrophy
Effective therapies for facioscapulohumeral muscular dystrophy (FSHD) are currently limited. Recombinant human growth hormone (rHGH) combined with testosterone (combination therapy) may have meaningful clinical effects on ambulation, strength, muscle mass, and disease burden. As such, combination therapy has the potential to limit disease progression and functional decline in individuals with muscular dystrophy. The objective of this study was to evaluate the safety, tolerability, and potential efficacy of combination therapy in adult men with FSHD. This investigator-initiated, single-center (University of Rochester), single-arm, proof-of-concept study evaluated the safety and tolerability of combination therapy in ambulatory adult men with FSHD. Participants received daily rHGH combined with testosterone enanthate injections every 2 weeks for 24 weeks, followed by a 12-week washout period. Participants underwent serial safety and laboratory assessments to monitor safety and tolerability during the study. Participants were also evaluated for changes from baseline in lean body mass (LBM) and fat mass, measured by dual-energy X-ray absorptiometry; ambulation, measured by 6-minute walk distance; strength; clinical function, measured using the FSHD-Composite Outcome Measure (FSHD-COM); and patient-reported disease burden, measured by the FSHD Health Index (FSHD-HI). Nineteen of 20 participants completed the study, with no participants experiencing a serious adverse event. The most common adverse event was mild injection site reaction at the rHGH and/or testosterone injection site. After 24 weeks, LBM improved by 2.21 kilograms (95% CI 1.35-3.07; p < 0.0001), fat mass decreased by 1.30 kilograms (95% CI -2.56 to -0.04; p = 0.04), 6-minute walk distance increased by 37.3 m (95% CI 18.3-56.9; p = 0.001), overall strength (average % of predicted normal) increased by 3% (95% CI 0.3-5.6; p = 0.03), clinical function (FSHD-COM) improved by 2.4 points (95% CI 4.0-0.8; p = 0.006), and total disease burden (FSHD-HI) decreased by 6.1 points (95% CI -12.0 to -0.2; p = 0.04). Combination therapy was safe and well tolerated in men with FSHD. Participants experienced improvements in ambulation, strength, muscle mass, and disease burden after receiving this study intervention. Larger randomized, double-blind, placebo-controlled trials are needed to further investigate this promising therapeutic approach. Registered on ClinicalTrials.gov: NCT03123913.
- 1 April 2025
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 18 (4) , e013196
Physical Activity Reduction in Patients Following ICD Therapy
- 1 April 2025
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 18 (4) , e013196
Physical Activity Reduction in Patients Following ICD Therapy
- Open Access
- 6 February 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (3) , e028902
Risk Prediction in Male Adolescents With Congenital Long QT Syndrome: Implications for Sex‐Specific Risk Stratification in Potassium Channel‐Mediated Long QT Syndrome
Background: Sex‐specific risk management may improve outcomes in congenital long QT syndrome (LQTS). We recently developed a prediction score for cardiac events (CEs) and life‐threatening events (LTEs) in postadolescent women with LQTS. In the present study, we aimed to develop personalized risk estimates for the burden of CEs and LTEs in male adolescents with potassium channel‐mediated LQTS. Methods and Results: The prognostic model was derived from the LQTS Registry headquartered in Rochester, NY, comprising 611 LQT1 or LQT2 male adolescents from age 10 through 20 years, using the following variables: genotype/mutation location, QTc‐specific thresholds, history of syncope, and β‐blocker therapy. Anderson‐Gill modeling was performed for the end point of CE burden (total number of syncope, aborted cardiac arrest, and appropriate defibrillator shocks). The applicability of the CE prediction model was tested for the end point of the first LTE (excluding syncope and adding sudden cardiac death) using Cox modeling. A total of 270 CEs occurred during follow‐up. The genotype–phenotype risk prediction model identified low‐, intermediate‐, and high‐risk groups, comprising 74%, 14%, and 12% of the study population, respectively. Compared with the low‐risk group, high‐risk male subjects experienced a pronounced 5.2‐fold increased risk of recurrent CEs ( P P =0.004) increased risk . At age 20 years, the low‐, intermediate‐, and high‐risk adolescent male patients had on average 0.3, 0.6, and 1.4 CEs per person, respectively. Corresponding 10‐year adjusted probabilities for a first LTE were 2%, 6%, and 8%. Conclusions: Personalized genotype–phenotype risk estimates can be used to guide sex‐specific management in male adolescents with potassium channel‐mediated LQTS.
- 6 February 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (3) , e028902
Open AccessRisk Prediction in Male Adolescents With Congenital Long QT Syndrome: Implications for Sex‐Specific Risk Stratification in Potassium Channel‐Mediated Long QT Syndrome
Background: Sex‐specific risk management may improve outcomes in congenital long QT syndrome (LQTS). We recently developed a prediction score for cardiac events (CEs) and life‐threatening events (LTEs) in postadolescent women with LQTS. In the present study, we aimed to develop personalized risk estimates for the burden of CEs and LTEs in male adolescents with potassium channel‐mediated LQTS. Methods and Results: The prognostic model was derived from the LQTS Registry headquartered in Rochester, NY, comprising 611 LQT1 or LQT2 male adolescents from age 10 through 20 years, using the following variables: genotype/mutation location, QTc‐specific thresholds, history of syncope, and β‐blocker therapy. Anderson‐Gill modeling was performed for the end point of CE burden (total number of syncope, aborted cardiac arrest, and appropriate defibrillator shocks). The applicability of the CE prediction model was tested for the end point of the first LTE (excluding syncope and adding sudden cardiac death) using Cox modeling. A total of 270 CEs occurred during follow‐up. The genotype–phenotype risk prediction model identified low‐, intermediate‐, and high‐risk groups, comprising 74%, 14%, and 12% of the study population, respectively. Compared with the low‐risk group, high‐risk male subjects experienced a pronounced 5.2‐fold increased risk of recurrent CEs ( P P =0.004) increased risk . At age 20 years, the low‐, intermediate‐, and high‐risk adolescent male patients had on average 0.3, 0.6, and 1.4 CEs per person, respectively. Corresponding 10‐year adjusted probabilities for a first LTE were 2%, 6%, and 8%. Conclusions: Personalized genotype–phenotype risk estimates can be used to guide sex‐specific management in male adolescents with potassium channel‐mediated LQTS.
- Open Access
Risk Stratification for Ventricular Tachyarrhythmia in Patients with Non-Ischemic Cardiomyopathy
Background: The implantable cardioverter defibrillator reduces mortality among patients with heart failure (HF) due to ischemic heart disease. Clinical trial data have called into question the benefit of an ICD in patients with HF due to non-ischemic cardiomyopathy (NICM). Objective: We developed a risk stratification score for ventricular tachyarrhythmia (VTA) among patients with NICM receiving a primary prevention ICD. Methods: The study population comprised of 1,515 patients with NICM who were enrolled in the landmark MADIT trials. Fine and Gray analysis was used to develop a model to predict the occurrence of VTAs and ICD therapies while accounting for the competing risk of non-arrhythmic mortality. External validation was carried out in the RAID Trial population. Results: Four risk factors associated with increased risk for VTA were identified: male sex, left ventricular ejection fraction ≤25%, no indication for cardiac resynchronization therapy with a defibrillator (CRT-D), and Black race. A score was generated based on this model and patients were stratified into low (N=390), intermediate (N=728), and high-risk (N=387) groups. The five-year cumulative incidences of VTA were 15%, 24%, 42% respectively. Application of score groups for the secondary endpoints of Fast VT or VF and Appropriate ICD Shock revealed similar findings. Recurrent event analysis yielded consistent results. The AUC in the validation cohort for the endpoint of Appropriate ICD Shock was 69.3. Conclusions: Our study shows that patients with NICM can be risk stratified using demographic and clinical variables and may be used when evaluating such patients for a primary prevention ICD. CONDENSED Data regarding the effectiveness of the ICD is lacking in patients with HF and NICM. The purpose of this study was to develop a risk score for ventricular tachyarrhythmia (VTA) among patients with NICM. We included patients from the MADIT trials to generate a risk score. Four risk factors associated with increased risk for VTA were identified and incorporated into the score. Patients were stratified into low, intermediate, and high-risk groups. The five-year cumulative incidences of VTA were 15%, 24%, 42% respectively. Our risk prediction model can support patient-physician shared decision making regarding primary ICD implantation in patients with NICM.
Open AccessRisk Stratification for Ventricular Tachyarrhythmia in Patients with Non-Ischemic Cardiomyopathy
Background: The implantable cardioverter defibrillator reduces mortality among patients with heart failure (HF) due to ischemic heart disease. Clinical trial data have called into question the benefit of an ICD in patients with HF due to non-ischemic cardiomyopathy (NICM). Objective: We developed a risk stratification score for ventricular tachyarrhythmia (VTA) among patients with NICM receiving a primary prevention ICD. Methods: The study population comprised of 1,515 patients with NICM who were enrolled in the landmark MADIT trials. Fine and Gray analysis was used to develop a model to predict the occurrence of VTAs and ICD therapies while accounting for the competing risk of non-arrhythmic mortality. External validation was carried out in the RAID Trial population. Results: Four risk factors associated with increased risk for VTA were identified: male sex, left ventricular ejection fraction ≤25%, no indication for cardiac resynchronization therapy with a defibrillator (CRT-D), and Black race. A score was generated based on this model and patients were stratified into low (N=390), intermediate (N=728), and high-risk (N=387) groups. The five-year cumulative incidences of VTA were 15%, 24%, 42% respectively. Application of score groups for the secondary endpoints of Fast VT or VF and Appropriate ICD Shock revealed similar findings. Recurrent event analysis yielded consistent results. The AUC in the validation cohort for the endpoint of Appropriate ICD Shock was 69.3. Conclusions: Our study shows that patients with NICM can be risk stratified using demographic and clinical variables and may be used when evaluating such patients for a primary prevention ICD. CONDENSED Data regarding the effectiveness of the ICD is lacking in patients with HF and NICM. The purpose of this study was to develop a risk score for ventricular tachyarrhythmia (VTA) among patients with NICM. We included patients from the MADIT trials to generate a risk score. Four risk factors associated with increased risk for VTA were identified and incorporated into the score. Patients were stratified into low, intermediate, and high-risk groups. The five-year cumulative incidences of VTA were 15%, 24%, 42% respectively. Our risk prediction model can support patient-physician shared decision making regarding primary ICD implantation in patients with NICM.
- 1 March 2021
- Published by Elsevier in The American Journal of Cardiology
- Vol. 143, 74-79
Systolic Blood Pressure and Risk for Ventricular Arrhythmia in Patients With an Implantable Cardioverter Defibrillator
- 1 March 2021
- Published by Elsevier in The American Journal of Cardiology
- Vol. 143, 74-79
Systolic Blood Pressure and Risk for Ventricular Arrhythmia in Patients With an Implantable Cardioverter Defibrillator
- 1 October 2020
- Published by Elsevier in The American Journal of Cardiology
- Vol. 132, 79-86
Utility of 6-Minute Walk Test to Predict Response to Cardiac Resynchronization Therapy in Patients With Mild Heart Failure
- 1 October 2020
- Published by Elsevier in The American Journal of Cardiology
- Vol. 132, 79-86
Utility of 6-Minute Walk Test to Predict Response to Cardiac Resynchronization Therapy in Patients With Mild Heart Failure